Summit Therapeutics Inc. - Common Stock — Cash Flow (NASDAQ:SMMT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -48.11 M-72.59 M-41.58 M-76.76 M-142.11 M-322.93 M -384.05 M Cash from investing activities -421 K-306 K-624 K-587.77 M-205.34 M-174.31 M -334.66 M Cash from financing activities 50.55 M77.92 M620.24 M86.51 M381.23 M617.53 M 613.65 M Free cash flow -48.11 M-72.59 M-41.58 M-76.76 M-142.11 M-322.93 M -384.05 M

News

My Top 5 Pharma Stocks Wall Street Ignores

Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet (NASDAQ:SMMT)

Summit Therapeutics: Getting A Foot In The Door Isn't Getting Through It (NASDAQ:SMMT)

3 Stocks Flashing Positive Insider Buying Signals - TipRanks.com

Stocks Settle Sharply Lower on Escalating Middle East Tensions

Stocks Resume Decline as Chipmakers and AI Companies Fall

Stocks Fall on Weakness in Tech and Trucking Companies

Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To Come (NYSE:EBS)

Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

The Era of the One-Size-Fits-All Cancer Drug Is Ending

All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy

Summit Therapeutics Inc. (SMMT) Discusses Plenary Session Updates and Recent Clinical Data Following Major Oncology Congress - Slideshow (NASDAQ:SMMT) 2026-06-03